Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

Journal of Clinical Oncology

Volumn 27, Issue 17, 2009, Pages 2823-2830

  Hauschild, Axel ^a   Agarwala, Sanjiv S ^a   Trefzer, Uwe ^a   Hogg, David ^a   Robert, Caroline ^a   Hersey, Peter ^a   Eggermont, Alexander ^a   Grabbe, Stephan ^a   Gonzalez, Rene ^a   Gille, Jens ^a   Peschel, Christian ^a   Schadendorf, Dirk ^a   Garbe, Claus ^a   O'Day, Steven ^a   Daud, Adil ^a   Michael White, J ^a   Xia, Chenghua ^a   Patel, Kiran ^a   Kirkwood, John M ^a   Keilholz, Ulrich ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DACARBAZINE; PACLITAXEL; PLACEBO; SORAFENIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LEUKOCYTE COUNT; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SAMPLE SIZE; SENSORY NEUROPATHY; SIDE EFFECT; SKIN EXFOLIATION; SKIN MANIFESTATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; AGED; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649909568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.7636     Document Type: Article

References (34)

1. Fecher LA, Cummings SD, Keefe MJ, et al: Toward a molecular classification of melanoma. J Clin Oncol 25:1606-1620, 2007
2. Cancer facts and figures, 2006. American Cancer Society, Atlanta, GA. http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf
3. Kim CJ, Reintgen DS, Balch CM: The new melanoma staging system. Cancer Control 9:9-15, 2002
4. Balch CM, Reintgen DS, Kirkwood JM, et al: Cutaneous melanoma, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, pp 1935-1993
5. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
6. Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 365:687-701, 2005
7. Bedikian AY, Millward M, Pehamberger H, et al: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-4745, 2006
8. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 22:1118-1125, 2004
9. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
10. Eggermont AM, Kirkwood JM: Re-evaluating the role of dacarbazine in metastatic melanoma: What have we learned in 30 years? Eur J Cancer 40:1825-1836, 2004
11. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
12. Legha SS, Ring S, Papadopoulos N, et al: A phase II trial of taxol in metastatic melanoma. Cancer 65:2478-2481, 1990
13. Zimpfer-Rechner C, Hofmann U, Figl R, et al: Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: A multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 13:531-536, 2003
14. Einzig AI, Hochster H, Wiernik PH, et al: A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 9:59-64, 1991
15. Hodi FS, Soiffer RJ, Clark J, et al: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 25:283-286, 2002
16. Bedikian AY, Weiss GR, Legha SS, et al: Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 13:2895-2899, 1995
17. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
18. Sharma A, Trivedi NR, Zimmerman MA, et al: Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65:2412-2421, 2005
19. Carter CA, Chen C, Brink C, et al: Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 59:183-195, 2007
20. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
21. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505-2512, 2006
22. Eisen T, Ahmad T, Flaherty KT, et al: Sorafenib in advanced melanoma: A phase II randomised discontinuation trial analysis. Br J Cancer 95:581-586, 2006
23. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. NEJM 356:125-134, 2007
24. Llovet J, Ricci S, Mazzaferro V, et al: Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 25:1s, 2007 (suppl; abstr LBA1)
25. Richly H, Kupsch P, Passage K, et al: Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer. Int J Clin Pharmacol Ther 42:650-651, 2004
26. Kupsch P, Henning BF, Passarge K, et al: Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196, 2005
27. Flaherty KT, Brose M, Schuchter LM, et al: Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: Progression-free survival and response versus b-raf status. Ann Oncol 17: iii33, 2006 (abstr)
28. Richly H, Henning BF, Kupsch P, et al: Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 17:866-873, 2006
29. Siu LL, Awada A, Takimoto CH, et al: Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144-151, 2006
30. Schiller JH, Flaherty KT, Redlinger M, et al: Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. J Clin Oncol 24:412s, 2006 (suppl; abstr 7194)
31. McDermott DF, Sosman JA, Gonzalez R, et al: Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 Study Group. J Clin Oncol 26:2178-2185, 2008
32. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
33. Amaravadi R, Schuchter LM, McDermott DF, et al: Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. J Clin Oncol 25:478s, 2007 (suppl; abstr 8527)
34. Eisen T, Marais R, Affolter A, et al: An openlabel phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. J Clin Oncol 25:479s, 2007 (suppl; abstr 8529)